Drug intelligence / Profile preview

Olea europaea allergen extract

Development stage
Phase 4
Lead developer
ALK Abelló
Modality
Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous, Intradermal
01

Overview

Olea europaea allergen extract is a form of allergen-specific immunotherapy (SIT) used to treat respiratory allergies, such as allergic rhinoconjunctivitis and asthma, triggered by sensitization to olive pollen. It functions by gradually desensitizing the patient's immune system through the administration of increasing doses of the allergen. This process aims to induce immunological tolerance, marked by a shift in the immune response that includes an increase in allergen-specific IgG4 antibodies and a decrease in IgE levels and skin reactivity. Clinical trial data describes a subcutaneous (SCIT) formulation adsorbed on aluminium hydroxide, developed by ALK-Abelló, which allows for a short, 6-week up-dosing schedule. [2, 3]

Brand names
Alutard SQAvanzAlustalLAISPollinex
Other names
olive pollen allergen extractolive pollen extract
02

Targets

Immunoglobulin E (IgE) specific for Olea europaea allergens

Beyond the preview

Go deeper on Olea europaea allergen extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olea europaea allergen extract.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call